

Ecole des Hautes Etudes en santé Publique

MASTER DE SANTE PUBLIQUE / MASTER OF PUBLIC HEALTH

Jean-Paul MOATTI

Inserm

Institut national
de la santé et de la recherche médicale

05CUF CV Directeur
UMR SE4S INSERM/IRD/UNiv. Méditerranée

Jean-Paul, Victor, MOATTI

Né à Tunis, Tunisie le 13 Août 1951

Professeur à l'UFR de Sciences Economiques & Gestion de l'Université de la Méditerranée (Aix_Marseille II)
– depuis Janvier 1995.

Directeur de l'Unité INSERM 379 (Epidémiologie & Sciences Sociales Appliquées à l'Innovation Médicale) –
depuis Janvier 1994.

Directeur de l'IFR 134 (Sciences Humaines Economiques & Sociales de la Santé & d'Aix-Marseille) – depuis
Janvier 2004.

Thèse de Sciences Economiques à l'Université de Paris I (1986)

Lauréat du Programme Environnement du German Marshall Fund des Etats-Unis (1987)

Chevalier dans l'Ordre National du Mérite (1996).

Membre du Advisory Committee for Health Research (ACHR) de l'Organisation Mondiale de la Santé

Président de la Commission Interdisciplinaire 42 (Santé & Société) et Comité National du CNRS

Président du Conseil Scientifique de l'Institut National de Prévention et d'Education pour la Santé (INPES)

Président du Comité Scientifique Sectoriel 5 « Recherches en santé publique, sciences de l'homme et de
la société » de l'Agence Nationale de Recherches sur le Sida et les Hépatites (ANRS)

Co-directeur du Master Recherche « Ingénierie des systèmes de santé » de l'Université de la
Méditerranée

Co-responsable de l'axe « Sciences Sociales » du Cancéropôle Provence-Alpes-Côte d'Azur

Responsable du Cours Economics of Aids (Summer Course of Harvard School of Public Health,
Boston)

Membre du Conseil d'Administration du Collège des Economistes de la Santé Français (CES)

Membre des Comités de Rédaction des Revues AIDS, AIDS CARE, International Journal of Technology
Assessment in Health Care, Health Services and Outcomes Research Methodology.

Membre de la Commission de Spécialistes d'Economie des Universités de la Méditerranée et de Lyon I

PRINCIPALES PUBLICATIONS 2001-2006

Peretti-Watel, P, Moatti, JP. **Understanding risk behaviours: how the sociology of deviance may
contribute? The case of drug-taking.** *Social Science & Medicine* 63, 2006, Pages 675-679

Lasserre, P, Moatti, JP, Soubeyran, A. **Early initiation of highly active antiretroviral therapies for
AIDS: dynamic choice with endogenous and exogenous learning.** *Journal Of Health Economics*,
25, 2006, 579-598.

Cissé, B, Luchini S, Moatti JP. **Progressivity and horizontal equity in health care finance and
delivery: What about Africa?** *Health Policy, In Press*

Marino, Patricia; Siani, Carole; Roché, Henri; Moatti, JP. **Impact of uncertainty on cost-effectiveness analysis of
medical strategies: the case of high-dose chemotherapy for breast cancer patients**

International Journal Of Technology Assessment In Health Care, 21, 2005, 342-350.

Mataria, A, Donaldson, C, Luchini, S, Moatti, JP. **A stated preference approach to assessing health
care-quality improvements in Palestine: from theoretical validity to policy implications.** *Journal of
Health Economics*, 23, 2004, 1285-1311.

Moatti, JP, Spire, B, Kazatchkine, M. **Drug resistance and adherence to HIV/AIDS antiretroviral
treatment: against a double standard between the north and the south.** *AIDS*, 18, 2004, S55-S61.

Cissé, B, Luchini S, Moatti JP. **Les effets des politiques de recouvrement des coûts sur la demande
de soins dans les PED : les raisons de résultats contradictoires.** *Revue Française d'Economie*, 2004,
7, 54-86.

Luchini, S, Protiere, C, Moatti, JP; **Eliciting Several Willingness to Pay in a Single Contingent
Valuation Survey: Application to Health Care,** *Health Economics*, 12, 2003, 51-64.

Moatti, J P; N'Doye, I; Hammer, S M; Hale, P; Kazatchkine, M. **Antiretroviral treatment for HIV
infection in developing countries: an attainable new paradigm.** *Nature Medicine*, 9, 2003, 1449-
1452.

Katzenstein D, Laga M, **Moatti JP**. Editorial: The evaluation of the HIV/AIDS Drug Access Initiatives in Côte d'Ivoire, Senegal and Uganda. *AIDS* 2003; 17 (suppl 3): S1-S4.

Loubiere S, Rotily M, **Moatti JP**. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. *International Journal Of Technology Assessment In Health Care*, 2003,1, 1-14.

Hoy M, Orsi F, Moatti JP. The impact of genetic testing on healthcare insurance. *Geneva Papers of Risk and Insurance* 2003, 28(2):203-221.

Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., **Moatti, JP**. Adherence to HAART in HIV-infected patients: from a predictive to a dynamic approach, *Social Science & Medicine*, 54, 10,2002, 1481-1496.

Sevilla, C., **Moatti, JP**, Julian-Reynier, C. et al. Testing for BRCA1 mutations: a cost-effectiveness analysis, *European Journal Of Human Genetics*, 10, 2002, 599-606.

Moatti, J P; Carrieri, M P; Spire, B. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. *AIDS*, 14, 2000, 151-155.

Obadia Y.; Perrin V.; Feroni I.; Vlahov D.; **Moatti J.P**. Injecting misuse of buprenorphine among French drug users, *Addiction*, 96, , 2001, 267-272.

Orsi, F, **Moatti, JP**. D'un droit de propriété intellectuelle sur le vivant aux firmes de génomique, *Economie et Prévision*, 150-151, 2001, 123-138.

Ouvrages: Moatti JP et al. (Eds). *Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. Issues and Challenges*. ANRS, Coll. Sciences Sociales & Sida, Paris, 2003.

Moatti JP. *Economie de la Santé* In : Encyclopaedia Universalis, Edition 2003.

PRINCIPALES PUBLICATIONS (avant 2001)

Bastide S.; **Moatti J.-P.**; Pages J.-P.; Fagnani F. Risk perception and social acceptability of technologies: The French case, *Risk Analysis*, 9, 1989, 215-223.

Dab W.; **Moatti J.-P.**; Bastide S.; Abenhaim L.; Brunet J.-B. Misconceptions about transmission of AIDS and attitudes toward prevention in the French general public, *AIDS*, 3, 1989, 433-437.

Moatti, J P; Bajos, N; Durbec, J P; Menard, C; Serrand, C. Determinants of condom use among French heterosexuals with multiple partners, *American Journal of Public Health*, 81, 1991, 106-109.

Moatti JP, Beltzer N, Dab W. Les modèles d'analyse des comportements à risque face à l'infection à VIH : Une conception trop étroite de la rationalité, *Population*, 5, 1993, 1505-1534.

Moatti J.P.; Chanut C.; Benech J.M. Researcher-driven versus policy-driven economic appraisal of health technologies: The case of France, *Social Science and Medicine*, 38, 12, 1994, 1625-1633.

Macquart-Moulin, G, Viens, P, Bouscary, M L; Maraninchi, D; **Moatti, J P**. Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care, *British Journal of Cancer*, 76, 12, 1997, s 1640-1645.

Rey D.; Carrieri M.-P.; Obadia Y.; Pradier C.; **Moatti J.-P**. Mandatory prenatal screening for the human immunodeficiency virus: The experience in south-eastern France of a national policy, 1992-1994, *British Journal of Obstetrics and Gynaecology*, 105, 1998, 269-274

.Obadia Y.; Feroni I.; Perrin V.; Vlahov D.; **Moatti J.-P**. Syringe vending machines for injection drug users: An experiment in Marseille, France, *American Journal of Public Health*, 89, 1999, 1852-1854.

Moatti J.-P.; Souteyrand Y. Editorial: HIV/AIDS social and behavioural research: Past advances and thoughts about the future, *Social Science and Medicine*, 50, 11, 2000, 1519-1532.

Macquart-Moulin G.; Viens P.; **Moatti J.-P** et al. High-dose sequential chemotherapy for inflammatory breast cancer patients: Does impact on quality of life jeopardize feasibility and acceptability of treatment? *Journal of Clinical Oncology*, 18, 2000, 754-764.

Ouvrages:

Moatti JP *Economie de la sécurité* INSERM, La Documentation Française, 1989.

Moatti JP, Mawas C. Evaluation des innovations biomédicales. INSERM, La Documentation Française, 1994.

Moatti J P et al. Aids in Europe. New challenges for the social sciences. Routledge, London, 2000

Cissé, B, Luchini S, **Moatti JP**. Les effets des politiques de recouvrement des coûts sur la demande de soins dans les PED : les raisons de résultats contradictoires. *Revue Française d'Economie*, 2004, 7, 54-86.

Luchini, S, Protiere, C, **Moatti, JP**; Eliciting Several Willingness to Pay in a Single Contingent Valuation Survey: Application to Health Care, *Health Economics*, 12, 2003, 51-64.

Moatti, J P; N'Doye, I; Hammer, S M; Hale, P; Kazatchkine, M. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. *Nature Medicine*, 9, 2003, 1449-1452.

Katzenstein D, Laga M, **Moatti JP**. Editorial: The evaluation of the HIV/AIDS Drug Access Initiatives in Côte d'Ivoire, Senegal and Uganda. *AIDS* 2003; 17 (suppl 3): S1-S4.

Loubiere S, Rotily M, **Moatti JP**. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. *International Journal Of Technology Assessment In Health Care*, 2003,1, 1-14.

Hoy M, Orsi F, Moatti JP. The impact of genetic testing on healthcare insurance. *Geneva Papers of Risk and Insurance* 2003, 28(2):203-221.

Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., **Moatti, JP**. Adherence to HAART in HIV-infected patients: from a predictive to a dynamic approach, *Social Science & Medicine*, 54, 10,2002, 1481-1496.

Sevilla, C., **Moatti, JP**, Julian-Reynier, C. et al. Testing for BRCA1 mutations: a cost-effectiveness analysis, *European Journal Of Human Genetics*, 10, 2002, 599-606.

Moatti, J P; Carrieri, M P; Spire, Betal. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. *AIDS*, 14, 2000, 151-155.
Obadia Y.; Perrin V.; Feroni I.; Vlahov D.; Moatti J.P. **Injecting misuse of buprenorphine among French drug users,** *Addiction*, 96, , 2001, 267-272.

Orsi, F, **Moatti, JP. D'un droit de propriété intellectuelle sur le vivant aux firmes de génomique,** *Economie et Prévision*, 150-151, 2001, 123-138.

Ouvrages: Moatti JP et al. (Eds). *Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. Issues and Challenges.* ANRS, Coll. Sciences Sociales & Sida, Paris, 2003.

Moatti JP. *Economie de la Santé* In : Encyclopaedia Universalis, Edition 2003.